

30 May 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Outcome of Board Meeting held on 30 May 2022

Ref: Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015

Dear Sir/Madam,

With reference to the above subject, and pursuant to Regulation 30 of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, we would like to inform you that the meeting of the Board of Directors of the Company held today i.e., Monday, 30 May 2022, the Board of Directors of the Company, inter alia, discussed, considered, and approved the following:

- a) Audited financial results (both standalone and consolidated) for the quarter and financial year ended 31 March 2022;
- b) Statement of Assets and Liabilities, Balance Sheet and Profit and Loss Account, Cash Flow Statement (both standalone and consolidated) as on 31 March 2022;
- c) Independent Auditors' Report thereon as on 31 March 2022; and
- d) Incorporation of a wholly-owned subsidiary company.


Requisite details w.r.t. incorporation of wholly-owned subsidiary, in terms of Regulation 30 of SEBI (LODR) Regulations, read with SEBI Circular CIR/CFD/CMD/4/2015 dated 9 September 2015, are given separately.

The meeting commenced at 3.45 PM and concluded at 9.45 PM.

This is for your information and records.

Thank you!

For Banka BioLoo Limited

Sri Bala Aditya Yanamandra
Company Secretary & Compliance Office

30 May 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Submission of audited financial results (both standalone and consolidated) for the quarter and financial year ended 31 March 2022, Statement of Assets and Liabilities, Balance Sheet and Profit and Loss Account, Cash Flow Statement (both standalone and consolidated) along with Independent Auditor's Report thereon

Dear Sir/Madam,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and other applicable circular(s), we herewith enclose the following:

- Audited financial results (both standalone and consolidated) for the quarter and financial year ended 31 March 2022;
- Statement of Assets and Liabilities, Balance Sheet and Profit and Loss Account, Cash Flow Statement (both standalone and consolidated) as on 31 March 2022; and
- Independent Auditors' Report thereon as on 31 March 2022.

The aforesaid financial results and statements are duly approved and recommended by the Audit Committee in their meeting held on 30 May 2022.


These are also being made available on the website of the Company at www.bankabio.com.

We would like to inform you that P R S V & Co. LLP, Chartered Accountants, issued the Audit Reports with un-modified opinion on the audited standalone and consolidated financial results for financial year ended 31 March 2022. This Declaration is being given pursuant to Regulation 33 (1)(d) of the of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015, read with SEBI CIR/CFD/CMD/56/2016 dated 27 May 2016.

Kindly take the same on record.

Thank you!

For Banka BioLoo Limited

Sri Bala Aditya Yanamandra
Company Secretary and Compliance Officer

Encls. as above



Independent Auditor's Report on the Quarterly and Year to Date Audited Standalone Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended

To
The Board of Directors of
BANKA BIOLOO LIMITED

Report on the Audit of the Standalone Financial Results

Opinion

We have audited the accompanying Statement of Audited Standalone Financial Results of BANKA BIOLOO LIMITED ("the Company) for the quarter and year ended 31st March 2022 ("The Statement"), being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").

In our opinion and to the best of our information and according to the explanations given to us, the statement:

- a) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as modified by Circular No. CIR/CFD/FAC/62/2016 dated July, 5, 2016; and
- b) Gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India of the standalone net profit and other comprehensive income and other financial information of the Company for the quarter and year ended 31st March, 2022.

Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Standalone Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.



Responsibilities of Management for the Standalone Financial Results

The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related standalone financial statements which has been prepared in accordance with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Statements, Board of Directors are responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Board of Directors either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so.

Board of Directors are also responsible for overseeing the company's financial reporting process.

Auditor's Responsibilities for the Audit of the Standalone Financial Results

Our objectives are to obtain reasonable assurance about whether the Statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the Statement.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the Statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.



- d) Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the financial results or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- e) Evaluate the overall presentation, structure and content of the Statement, including the disclosures, and whether the Statement represents the underlying transactions and events in a manner that achieves fair presentation.


We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

Other Matter

The Statement includes the results for the Quarter ended 31st March 2022 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For PRSV & Co. LLP
Chartered Accountants
Firm's Registration No. S200016


Y. Venkateswarlu
Partner
Membership No. 222068



UDIN: 2222068AJXZJM4197

Place: Hyderabad
Date: 30 May 2022

BANKA BIOLOO LIMITED

Statement of STANDALONE Assets and Liabilities as at 31 March 2022

Particulars	Rs. In Lacs	
	Audited	
	As at 31 March, 2022	As at 31 March, 2021
ASSETS		
Non-current assets		
Property, Plant and Equipment	404.75	386.51
(i) Tangible assets	10.19	12.48
(ii) Intangible assets	241.78	-
(iii) Capital work in progress	202.24	109.65
(iv) Right of use asset	-	-
Financial assets		
Investments	435.76	3.50
Other financial assets	216.90	476.43
Deffered tax assets (net)	7.97	1.32
Other Non current assets	-	47.71
Total non-current assets	1,519.60	1,037.59
Current assets		
Inventories	1,062.71	803.03
Financial assets		
Trade receivables	1,737.87	1,167.81
Cash and cash equivalents	29.55	180.46
Other bank balances	389.53	466.67
Other financial assets	216.20	252.08
Income tax assets	161.01	120.02
Other current assets	843.51	609.62
Total current assets	4,440.38	3,599.67
Total assets	5,959.97	4,637.26
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,084.66	1,028.11
Other equity	2,660.84	1,974.86
Total equity	3,745.50	3,002.97
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	614.83	586.81
Lease liabilities	168.11	95.30
Provisions	29.12	32.76
Deferred tax liabilities (Net)	-	-
Total Non-current liabilities	812.06	714.88
Current liabilities		
Financial Liabilities		
Short-term borrowings	435.35	168.19
Trade payables		
Dues to MSME Creditors	7.70	-
Dues to other than MSME Creditors	247.80	248.72
Short-term lease liabilities	46.33	16.39
Other financial liabilities	362.78	313.36
Other current liabilities	302.47	172.76
Total Current liabilities	1,402.42	919.42
Total Equity & Liabilities	5,959.97	4,637.26

For PRSV & Co. LLP
Chartered Accountants
FRN No. S200016

T. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date: 30.05.2022



FOR & ON BEHALF OF BOARD OF DIRECTORS

T.V. Rama Krishna
CFO & Executive Director
DIN: 07977695



BANKA BIOLOO LIMITED

Audited STANDALONE Statement of Financial Results for the quarter and year ended 31 March 2022


Rs. In Lacs

S. No	Particulars	Quarter ended			Year ended	
		Audited	Unaudited	Audited	Audited	Audited
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
1	Income					
	Revenue from Operations	1023.67	1005.42	962.61	3,863.38	3,045.76
	Other income	10.18	13.88	30.34	45.37	57.61
	Total Income	1033.85	1019.31	992.96	3,908.75	3,103.37
2	Expenses					
	Cost of materials consumed	106.02	223.03	281.18	774.66	702.22
	Changes in inventories of finished goods & work-in-progress	(13.64)	(25.60)	(192.76)	(107.80)	(321.13)
	Employee benefits expense	500.43	478.53	392.34	1774.16	1302.45
	Finance costs	45.62	43.78	48.83	173.13	151.45
	Depreciation and amortisation expense	27.73	25.86	20.26	94.06	59.73
	Other expenses	258.48	197.12	431.56	874.54	1021.65
	Total expenses	924.64	942.73	981.42	3,582.75	2,916.37
3	Profit/(loss) before tax	109.20	76.58	11.54	326.00	187.00
4	Tax expense					
	(1) Current tax	8.74	19.15	(33.70)	27.88	-
	(2) Taxes for earlier years	0.00	0.00	(19.29)	-	(19.29)
	(3) MAT Credit	0.00	0.00	-	-	-
	(4) Deferred tax	1.85	4.67	(6.41)	(7.75)	(14.36)
	Total Tax expense	10.59	23.81	(59.39)	20.13	(33.64)
5	Profit after tax	98.61	52.77	70.93	305.87	220.64
	Other comprehensive income					
	<i>Items that will not be reclassified to profit and loss</i>					
	Remeasurement of post-employment benefit obligations	4.51	-	27.16	4.51	27.16
	Income tax effect on items that will not be reclassified to	(1.10)	-	(6.65)	(1.10)	(6.65)
	Other comprehensive income for the year	3.40	-	20.51	3.40	20.51
	Total comprehensive income for the year	102.02	52.77	91.44	309.27	241.15
6	Paid up equity share capital (Face value Rs. 10/- each)	1084.66	1028.11	1028.11	1,084.66	1,028.11
7	Earnings per share					
	Basic and Diluted Earnings per share (in Rs.)	0.96	0.51	0.69	2.97	2.15
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualised)

For PRSV & Co. LLP
Chartered Accountants
FRN No. S200016


Y. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date: 30.05.2022



FOR & ON BEHALF OF BOARD OF DIRECTORS

T.V. Rama Krishna
CFO & Executive Director
DIN: 07977695



BANKA BIOLOO LIMITED

Standalone statement of Cash flows for the year ending 31.03.2022

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
A. Cash flows from/(used in) operating activities		
Net profit before tax	326.00	187.00
Adjustments for:	-	-
Depreciation and amortisation expense	94.06	59.73
Finance cost	155.63	148.12
Interest on Lease Rentals	17.50	3.32
Loss on sale of asset	0.25	-
Impairment of assets	-	-
Other Comprehensive	-	-
Interest income	(45.37)	(50.42)
Operating profit before working capital changes	548.07	347.76
<i>Changes in operating assets and liabilities</i>		
(Increase)/decrease in inventories	(259.68)	(426.84)
(Increase) in trade receivables	(570.06)	328.97
(Increase)/decrease in other financial assets	295.40	442.98
(Increase)/decrease in other current assets	(233.89)	129.81
(Increase)/decrease in other non-current assets	47.71	(27.99)
(Increase)/decrease in other assets	(2.20)	85.09
Increase/(Decrease) in trade payables	6.78	(71.25)
Increase/(Decrease) in other financial liabilities	49.41	66.96
Increase/(Decrease) in other current liabilities	129.71	(155.08)
Increase/(Decrease) provisions	0.86	(17.14)
Cash (used in)/from operating activities	12.11	703.26
Tax paid	66.68	120.02
Net cash (used in)/ from operating activities	(54.58)	583.25
B. Cash flow from/(used in) investing activity		
Purchase of fixed assets	(316.04)	(50.93)
Sale of Asset	0.70	-
(Increase)/decrease in investments	1.00	(3.50)
Interest received	45.37	50.42
Net cash (used in)/from investing activities	(268.97)	(4.02)
C. Cash flows from/(used in) financing activities		
Repayment /proceeds of long term borrowings	28.02	(158.24)
Increase/(decrease) in short term borrowing	267.16	(10.73)
Payment of principle portion of lease liabilities	(44.05)	(7.05)
Interest paid	(155.63)	(148.12)
Dividend paid	-	(41.12)
Net cash (used in)/from financing activities	95.50	(365.27)
Net increase / (decrease) in cash and cash equivalents	(228.05)	213.96
Add: Cash and cash equivalents at the beginning of the year	647.13	433.17
Less: Bank deposits with less than 12 months maturity	389.53	466.67
Cash and cash equivalents at the end of the year	29.55	180.46

For PRSV & Co.LLP

Chartered Accountants

FRN No: S-200016


Y.Venkateswarlu

Partner

M.No. 222068

Place : Hyderabad

Date: 30.05.2022



For and on behalf of Board of Directors

T.V. Rama Krishna

Executive Director & CFO

DIN: 07977695



Notes:

1. The above audited Standalone Financial Results were reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 30 May 2022.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The above Standalone Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
4. The Standalone Financial Results for the quarter and year ended 31 March 2022 have been prepared following the same accounting policies as these followed for the annual financial statements for the year ended 31st March 2022.
5. Based on the internal reporting provided to the Chief Operating Decision Maker, the standalone financial results relate to manufacturing, supplying and installation of Bio toilets and related AMOC services as the only reportable primary segment of the Company as per the Ind AS 108 "Operating Segments".
6. The figures of the quarter ended March are the balancing figures between audited figures in respect of full financial year up to March and the unaudited published year to date figures up to December of each year, being the date of the end of third quarter of respective financial years which were subject to limited review.
7. During the financial year ended 31st March 2018, the company has completed its initial public Offer (IPO) of 10,98,000 Equity Shares of Rs.10/- each at a price of Rs.115 per share (including a premium of Rs.105 per share).
8. Proceeds from Initial Public Offer of Equity Shares have been utilized as under:

S. No	Particulars	Projected Utilization of Funds as per Prospectus	Actual Utilization of Funds till 31.03.2022	Deviation/ Variation (if any)
1	Long Term Working Capital Requirement	797.88	797.88	
2	General Corporate Purpose	231.62	231.62	
3	Issue Related Expenses-Company portion	61.10	61.08	
4	Capital expenditure at existing inoculum at Aler	75.21	75.21	
5	Capital expenditure at proposed new unit at Ibrahimpatnam	96.89	26.42	
	Total	1,262.70	1192.21	-

9. The Company has considered internal and external information up to the date of approval of these standalone financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets.
10. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka Bioloo Limited

T.V. Rama Krishna

T.V. Rama Krishna
CFO & Executive Director
DIN: 07977695



Place: Hyderabad
Date: 30 May 2022



Independent Auditor's Report on the Quarterly and Year to Date Consolidated Financial Results of the Company Pursuant to the Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 as amended

TO
THE Board of Directors of
BANKA BIOLOO LIMITED

Report on the Audit of the Consolidated Financial Results

Opinion

We have audited the accompanying statement of audited consolidated financial results of BANKA BIOLOO LIMITED ("the Holding Company) its wholly owned subsidiary entity and associate for the quarter and year ended 31st March 2022 ("the statement"), being submitted by the Holding Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular").

In our opinion and to the best of our information and according to the explanations given to us, the Statement

- a) Includes the results of the following entities

Holding Company

Banka Bioloo Limited

Wholly owned subsidiary

Enzotech Solutions Pvt Ltd

Associates

- a. Sai Banka SPV Pvt Ltd
b. Sustainable Sanitation Industry Association
- b) Is presented in accordance with the requirements of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 ("the Regulation") as amended, read with SEBI Circular No.CIR/CFD/CMD1/44/2019 dated March 29, 2019 ("the Circular"); and
- c) Gives a true and fair view in conformity with the applicable accounting standards and other accounting principles generally accepted in India of the consolidated net profit and other comprehensive income and other financial information of the Company for the quarter and year ended 31st March, 2022.



Basis for Opinion

We conducted our audit in accordance with the Standards on Auditing (SAs) specified under section 143(10) of the Companies Act, 2013. Our responsibilities under those Standards are further described in the Auditor's Responsibilities for the Audit of the Consolidated Financial Results section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India together with the ethical requirements that are relevant to our audit of the financial statements under the provisions of the Companies Act, 2013 and the Rules there under, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the Code of Ethics. We believe that the audit evidence obtained by us and other auditors in terms of their reports referred to in "Other Matter" paragraph below is sufficient and appropriate to provide a basis for our opinion.

Responsibilities of Management for the Consolidated Financial Statements

The statement, which is the responsibility of the Company's Management and approved by the Board of Directors, has been compiled from the related consolidated financial statements which has been prepared in accordance with the applicable accounting standards prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued there under and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. The respective Board of Directors of the companies included in the group are responsible for maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding of the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the Statement that give a true and fair view and are free from material misstatement, whether due to fraud or error, which have been used for the purpose of preparation of the Statement by the Directors of the Holding Company, as aforesaid.

In preparing the Statement, the respective Board of Directors of the companies included in the Group are responsible for assessing the ability of the Group to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the respective Board of Directors either intends to liquidate the Group or to cease operations, or has no realistic alternative but to do so.

The respective Board of Directors of the companies included in the Group are also responsible for overseeing the financial reporting process of the Group.

Auditor's Responsibilities for the Audit of the Consolidated Financial Results

Our objectives are to obtain reasonable assurance about whether the statement as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of the statement.



As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- a) Identify and assess the risks of material misstatement of the statement, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.
- b) Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances. Under section 143(3)(i) of the Companies Act, 2013, we are also responsible for expressing our opinion on whether the company has adequate internal financial controls system in place and the operating effectiveness of such controls.
- c) Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the Board of Directors.
- d) Obtain sufficient appropriate audit evidence regarding the financial results/financial information of the entities within the Group of which we are the independent auditors and whose financial information we have audited, to express an opinion on the Statement. We are responsible for the direction, supervision, and performance of the audit of the financial information of such entities included in the Statement, which have been audited by other auditors, such other auditors remain responsible for the direction, supervision and performance of the audits carried out by them . We remain solely responsible for our audit opinion.
- e) Evaluate the overall presentation, structure and content of the statement, including the disclosures, and whether the statement represents the underlying transactions and events in a manner that achieves fair presentation.

We communicate with those charged with governance of the Holding Company and such other entities included in the Statement of which we are independent auditors regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.



Other Matter


We did not audit the financial statements/financial information of wholly owned subsidiary included in the consolidated financial results, whose financial statements/financial information reflects total assets of 28,54,621 and total revenues of Rs. 11,70,000 and Rs.11,70,000 and for the quarter and year ended March 31, 2022, respectively, total profit and comprehensive income of 2,18,675 and 2,18,675 for the quarter and year ended March 31, 2022, as considered in the consolidated Audited financial results. This financial statements/financial information have been audited/reviewed by other auditors whose reports have been furnished to us by the management and our opinion and conclusion on the statement, in so far as it relates to the amounts and disclosures included in respect of the wholly owned subsidiary is solely on the reports of the author auditors and the procedures performed by us as stated under auditor's responsibilities stated above. We also did not audit the financial statements/financial information of 2 associates as mentioned above included in the consolidated financial results, this financial statements/financial information has been furnished to us by the Management and our opinion on the Statement, in so far as it relates to the amounts and disclosures included in respect of the subsidiary and associates, is based solely on those statements/financials' information provided by the management and those amounts considered in the consolidated financial results are not material and very insignificant as compared to standalone financials of the Company.

The Statement includes the results for the Quarter ended 31st March 2022 being the balancing figure between audited figures in respect of the full financial year and the published year to date figures up to the third quarter of the current financial year which were subject to limited review by us, as required under the Listing Regulations.

For PRSV & Co. LLP

Chartered Accountants


Firm's Registration No. S200016


Y. Venkateswarlu

Partner

Membership No. 222068

UDIN: 2222068AJXZMF4543



Place: Hyderabad

Date: 30 May 2022

BANKA BIOLOO LIMITED
Statement of CONSOLIDATED Assets and Liabilities as at 31 March 2022

(Rs. In Lakhs)

Particulars	Audited	Audited
	As at 31 March, 2022	As at 31 March, 2021
ASSETS		
Non-current assets		
Property, Plant and Equipment		
(i) Tangible assets	432.67	386.51
(ii) Intangible assets	10.19	12.48
(iii) Capital work in progress	241.78	-
(iv) Right of use asset	202.24	109.65
Goodwill	31.51	-
Financial assets	-	-
Investments	5.01	2.33
Other financial assets	217.53	476.43
Deffered tax assets (net)	6.94	1.32
Other Non current assets	-	47.71
Total non-current assets	1,147.88	1,036.42
Current assets		
Inventories	1,340.56	803.03
Financial assets	-	-
Trade receivables	2,035.93	1,167.81
Cash and cash equivalents	31.92	181.47
Other bank balances	396.11	466.67
Other financial assets	356.85	252.08
Income tax assets	161.01	120.02
Other current assets	935.17	609.62
Total current assets	5,257.55	3,600.68
Total assets	6,405.43	4,637.10
EQUITY AND LIABILITIES		
Equity		
Equity share capital	1,084.66	1,028.11
Other equity	2,665.53	1,974.69
Equity attributable to shareholders of the company	3,750.19	3,002.81
Non-controlling interests	-	0.00
Total equity	3,750.19	3,002.81
Liabilities		
Non-current liabilities		
Financial Liabilities		
Borrowings	742.91	586.81
Lease liabilities	168.11	95.30
Provisions	29.12	32.76
Deferred tax liabilities (Net)	-	-
Total Non-current liabilities	940.14	714.88
Current liabilities		
Financial Liabilities		
Borrowings	529.73	168.19
Trade payables	-	-
Dues to MSME Creditors	7.70	-
Dues to other than MSME Creditors	358.23	248.72
Lease Liabilities	46.33	16.39
Other financial liabilities	497.16	313.36
Other current liabilities	275.95	172.76
Total Current liabilities	1,715.11	919.42
Total Equity & Liabilities	6,405.43	4,637.10

For PRSV & Co. LLP
Chartered Accountants
FRN No. S200016

Y. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date: 30.05.2022



FOR & ON BEHALF OF BOARD OF DIRECTORS

T.V. Rama Krishna
CFO & Executive Director
DIN: 07977695



BANKA BIOLOO LIMITED

Audited CONSOLIDATED Statement of Financial Results for the quarter and year ended 31 March 2022


Rs. Lacs

S. No	Particulars	Quarter ended			Year ended	
		31.03.2022	31.12.2021	31.03.2021	31.03.2022	31.03.2021
		Audited	Unaudited	Audited	Audited	Audited
1	Income					
	Revenue from Operations	1,035.37	1,005.42	962.61	3,875.08	3,045.76
	Other income	10.18	13.88	30.35	45.37	57.62
	Total Income	1,045.55	1,019.31	992.97	3,920.45	3,103.38
2	Expenses					
	Cost of materials consumed	110.03	223.03	281.18	778.67	702.22
	Changes in inventories of finished goods & work-in-progress	(12.38)	(25.60)	(192.76)	(106.54)	(321.13)
	Employee benefits expense	502.69	478.53	392.34	1,776.42	1,302.45
	Finance costs	46.28	43.78	48.83	173.78	151.45
	Depreciation and amortisation expense	27.81	25.86	20.26	94.15	59.73
	Other expenses	259.73	197.12	431.56	875.79	1,021.65
	Total expenses	934.16	942.73	981.42	3,592.27	2,916.37
3	Share of profit/(loss) of Associates	4.46	(0.20)	(0.17)	2.71	(0.17)
4	Profit/(loss) before tax	115.85	76.38	11.38	330.89	186.84
5	Tax expense					
	(1) Current tax	8.74	19.15	(33.70)	27.88	-
	(2) Taxes for earlier years	-	-	(19.29)	-	(19.29)
	(3) MAT Credit	-	-	-	-	-
	(4) Deferred tax	1.85	4.67	(6.41)	(7.75)	(14.36)
	Total Tax expense	10.59	23.81	(59.39)	20.13	(33.64)
6	Profit after tax	105.26	52.57	70.77	310.76	220.48
	Other comprehensive income					
	<i>Items that will not be reclassified to profit and loss</i>					
	Remeasurement of post-employment benefit obligations	4.51	0.00	27.16	4.51	27.16
	Income tax effect on items that will not be	(1.10)	-	(6.65)	(1.10)	(6.65)
	Other comprehensive income for the year	3.40	-	20.51	3.40	20.51
	Total comprehensive income for the year	108.66	52.57	91.28	314.17	240.99
	Attributable to					
	Shareholders of the Company	108.66	52.57	91.28	314.17	240.99
	Non controlling interest	-	-	-	-	-
7	Paid up equity share capital (Face value Rs. 10/- each)	1,084.66	1,028.11	1,028.11	1,084.66	1,028.11
8	Earnings per share					
	Basic and Diluted Earnings per share (in Rs.)	1.02	0.51	0.69	3.02	2.14
		(Not annualised)	(Not annualised)	(Not annualised)	(Annualised)	(Annualised)

For PRSV & Co. LLP
Chartered Accountants
FRN No. S200016

Y. Venkateswarlu
Partner
M.No.222068

Place: Hyderabad
Date : 30.05.2022



FOR & ON BEHALF OF BOARD OF DIRECTORS

T.V. Rama Krishna
CFO & Executive Director
DIN: 07977695




BANKA BIOLOO LIMITED
Consolidated statement of Cash flows

Particulars	Year ended 31 March 2022	Year ended 31 March 2021
A. Cash flows from/(used in) operating activities		
Net profit before tax	330.89	186.84
Adjustments for:	-	-
Depreciation and amortisation expense	94.15	59.73
Finance cost	156.29	151.45
Interest on Lease Rentals	17.50	3.32
Loss on sale of asset	0.25	-
Interest income	(45.37)	(50.43)
Operating profit before working capital changes	553.70	350.91
<i>Changes in operating assets and liabilities</i>		
(Increase)/decrease in inventories	(259.68)	(426.84)
(Increase) in trade receivables	(570.06)	328.97
(Increase)/decrease in other financial assets	295.40	442.98
(Increase)/decrease in other current assets	(233.89)	129.81
(Increase)/decrease in other non-current assets	47.71	(27.99)
(Increase)/decrease in other assets	(2.20)	85.09
Increase/(Decrease) in trade payables	6.78	(71.25)
Increase/(Decrease) in other financial liabilities	49.41	66.96
Increase/(Decrease) in other current liabilities	134.69	(155.08)
Increase/(Decrease) provisions	0.86	(17.14)
Cash (used in)/from operating activities	22.72	706.41
Tax paid	66.68	120.02
Net cash (used in)/ from operating activities	(43.96)	586.40
B. Cash flow from/(used in) investing activity		
Purchase of fixed assets	(316.04)	(50.93)
Sale of Asset	0.70	-
(Increase)/decrease in investments	(1.68)	(2.33)
Interest received	45.37	50.43
Net cash (used in)/from investing activities	(271.65)	(2.83)
C. Cash flows from/(used in) financing activities		
Repayment /proceeds of long term borrowings	28.02	(158.24)
Increase/(decrease) in short term borrowing	267.16	(10.73)
Payment of principle portion of lease liabilities	(44.05)	(7.05)
Interest paid	(155.63)	(151.45)
Dividend paid	-	(41.12)
Net cash (used in)/from financing activities	95.50	(368.59)
Net increase /(decrease) in cash and cash equivalents	(220.12)	214.97
Add: Cash and cash equivalents at the beginning of the year	648.14	433.17
Less: Bank deposits with less than 12 months maturity	396.11	466.67
Cash and cash equivalents at the end of the year	31.92	181.47

For PRSV & Co.LLP
Chartered Accountants
FRN No: S200016

Y.Venkateswarlu
Partner
M.No. 222068

Place: Hyderabad
Date : 30.05.2022



For and on behalf of Board of Directors

T.V. Rama Krishna
Executive Director & CFO
DIN: 07977695



Notes:

1. The above statement of Audited Consolidated Financial Results was reviewed by the Audit Committee and then approved by the Board of Directors at their respective meetings held on 30 May 2022.
2. The Standalone Financial Results have been prepared in accordance with Indian Accounting Standards prescribed under section 133 of the Companies Act 2013 ("the Act") read with the relevant rules issued there under ("INDAS") and other accounting principles generally accepted in India and the guidelines issued by SEBI .
3. The figures of the quarter ended March are the balancing figures between audited figures in respect of full financial year up to March and the unaudited published year to date figures up to December of each year, being the date of the end of third quarter of respective financial years which were subject to limited review.
4. The consolidated financial results of the Group include the results of the Company and results of the following entities.

Name of the entity	Status
Enzotech Solutions Pvt Ltd	Wholly owned subsidiary
Sai Banka SPV Pvt Ltd	Associate
Sustainable Sanitation Industry Association	Associate

5. The above Consolidated Financial Results have been prepared in Compliance with Regulation 33 of SEBI (Listing Obligations and Disclosure requirements) Regulations 2015.
6. The Company has considered internal and external information up to the date of approval of these Consolidated financial results in assessing the recoverability of assets including trade receivables, unbilled receivables, based on which it expects to recover the carrying amount of these assets,
7. Figures of previous year / period have been regrouped / recast wherever necessary, in order to make them comparable.

For Banka Bioloo Limited

T.V. Rama Krishna

T.V. Rama Krishna
CFO & Executive Director
DIN: 07977695



Place: Hyderabad
Date: 30 May 2022

30 May 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31 March 2022


Dear Sir/Madam,

With reference to the above-cited subject, please find enclosed herewith the statement of deviation(s) or variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015 for the quarter and year ended 31 March 2022.

This is for your information and necessary records.

Thank you!

For Banka BioLoo Limited



Sri Bala Aditya Yanamandra
Company Secretary and Compliance Officer

Statement of Deviation(s) or Variation(s) under Regulation 32(1) of SEBI (LODR) Regulations, 2015

In reference to the compliance under Regulation 32(1)(a) & (b) of SEBI (LODR) Regulations, 2015, as required under regulation 32(8) of SEBI (LODR) Regulations, 2015, the Company hereby submits to National Stock Exchange, statement of deviation(s) or variation(s) for the quarter and year ended 31 March 2022.

a) Indicating deviations, if any, in the use of proceeds from the objects stated in the offer document or explanatory statement to the notice for the general meeting, as applicable:

We, hereby, inform you that there was no deviation in the utilisation of the proceeds of the public issue from the objects stated in the prospectus of the issue, as required under regulation 32(1)(a) of SEBI (LODR) Regulations, 2015.

b) Indicating category-wise variation (capital expenditure, sales and marketing, working capital etc.) between projected utilization of funds made by it in its offer document or explanatory statement to the notice for the general meeting, as applicable, and the actual utilisation of funds:

We, hereby, inform that there has been no variation in the use of the proceeds from the objects stated in the prospectus dated 23 January 2018, or explanatory statement to the notice of the Extra-Ordinary Meeting dated 16 November 2017, issued for initial public offering of securities, as per Regulation 32(1)(b) of SEBI (LODR) Regulations, 2015.

Thank you!

For Banka BioLoo Limited

T V Rama Krishna



**T V Rama Krishna
CFO & Executive Director
DIN 07977695**

30 May 2022

The Listing Department
National Stock Exchange of India Limited
Exchange Plaza C-1, Block G
Bandra Kurla Complex
Bandra (East)
Mumbai - 400051

Symbol: BANKA

Sub: Declaration Pursuant to Regulation 33(3)(d) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for Unmodified Opinion

Dear Sir/Madam,

I, T V Rama Krishna, Chief Financial Officer of Banka BioLoo Limited, hereby declare that the Company's Statutory Auditors P R S V & Co. LLP, Chartered Accountants, Hyderabad, has issued an Audit Report with an un-modified opinion/ unqualified opinion, on the standalone and consolidated audited financial results for the quarter and year ended 31 March 2022.

This Declaration is issued in compliance of Regulation 33(3)(d) of the SEBI (LODR) Regulations 2015, as amended vide its circular number CIR/CFD/CMD/56/2016 dated 27 May 2016.

Kindly take the same on record.

Thank you,

For Banka BioLoo Limited

T V Rama Krishna
CFO & Executive Director
DIN 07977695